Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
It definitely looks like a negative result overall with revenues falling 16% short of analyst estimates at US$37m. Statutory losses were US$0.10 per share, 58% bigger than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Akebia Therapeutics after the latest results. See our latest analysis for Akebia Therapeutics After the latest results, the three analysts covering Akebia Therapeutics are now predicting revenues of US$179.1m in 2025. If met, this would reflect a satisfactory 5.4% improvement in revenue compared to the last 12 months. Losses are expected to increase substantially, hitting US$0.26 per share. Yet prior to the latest earnings, the analysts h
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease [Yahoo! Finance]Yahoo! Finance
- Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseasePR Newswire
- Akebia Therapeutics to Present at the Jefferies London Healthcare ConferencePR Newswire
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
AKBA
Earnings
- 11/7/24 - Miss
AKBA
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- AKBA's page on the SEC website